Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Mirtazapine
Drug ID BADD_D01476
Description Mirtazapine is a tetracyclic _piperazino-azepine_ antidepressant agent that was initially approved for the treatment of major depressive disorder (MDD) in the Netherlands in 1994.[A177946] This drug was first manufactured by Organon Inc., and received FDA approval in 1997 for the treatment of major depressive disorder.[T595, L6157] The effects of this drug may be observed as early as 1 week after beginning therapy.[A178144,L6160] In addition to its beneficial effects in depression, mirtazapine has been reported to be efficacious in the off-label management of various other conditions. It may improve the symptoms of neurological disorders, reverse weight loss caused by medical conditions, improve sleep, and prevent nausea and vomiting after surgery.[A177811]
Indications and Usage This drug is indicated for the treatment of major depressive disorder and its associated symptoms.[FDA label] Mirtazapine has been used off-label for a variety of conditions including panic disorder, generalized anxiety disorder, dysthymia, tension headaches, hot flushes, post-traumatic stress disorder (PTSD), sleep disorders, substance abuse disorders, and sexual disorders, among others.[A177811,A177946]
Marketing Status approved
ATC Code N06AX11
DrugBank ID DB00370
KEGG ID D00563
MeSH ID D000078785
PubChem ID 4205
TTD Drug ID D05ZIK
NDC Product Code 76483-111; 78206-156; 0904-6519; 65862-032; 65977-0137; 13107-003; 50090-1057; 50090-2558; 55154-8145; 57237-007; 57237-011; 61919-153; 63187-554; 63629-2366; 65862-003; 68084-121; 68788-7754; 71335-0441; 71610-475; 76483-110; 38779-3076; 60312-0095; 43353-378; 45865-137; 55154-8335; 57664-501; 63629-5086; 63629-9255; 63739-099; 68071-2784; 68788-7251; 70518-0180; 70518-1309; 71335-1055; 71610-100; 71610-523; 71610-713; 0615-8078; 80425-0305; 45865-382; 51079-086; 57237-009; 57237-010; 60687-584; 63629-2368; 65862-021; 68084-119; 68084-120; 68788-7492; 70518-1838; 70518-2453; 71610-121; 0615-8268; 63187-206; 63629-2367; 63739-098; 66993-606; 68788-8459; 71610-115; 71610-717; 72578-105; 76483-112; 78206-160; 65862-031; 70600-004; 71052-108; 57237-012; 60505-0247; 61919-154; 63629-5085; 70518-1293; 70518-2582; 71205-481; 71335-1534; 72578-103; 72578-104; 12860-0030; 53296-0047; 60870-0117; 65862-001; 65862-023; 13107-001; 51407-351; 53002-1712; 53002-2712; 55700-249; 57664-500; 60505-0248; 63629-3346; 68071-2635; 68788-7324; 70518-2058; 71335-0286; 71335-0717; 12860-0076; 13107-032; 50090-2800; 57237-013; 63187-403; 68071-2884; 71335-0664; 42291-494; 51407-350; 60505-0249; 70518-1397; 70518-2581; 70518-2819; 71335-0964; 78206-161; 70600-037; 13107-031; 51407-352; 0378-3515; 0378-3545; 71335-1332; 0615-8269; 78206-158; 78206-159; 65862-022; 51079-087; 51079-088; 53002-1474; 55154-5355; 55154-7297; 57237-008; 57664-499; 63187-471; 63629-5537; 0378-3530; 12860-0077; 58032-0121; 60312-0096; 49999-629; 57664-510
UNII A051Q2099Q
Synonyms Mirtazapine | 6-Azamianserin | 6 Azamianserin | ORG 3770 | ORG-3770 | ORG3770 | Rexer | Remeron | Norset | Remergil | Zispin | Esmirtazapine | (S)-Mirtazapine | Org 50081 | (N-Methyl-11C)mirtazapine
Chemical Information
Molecular Formula C17H19N3
CAS Registry Number 85650-52-8
SMILES CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Lymphadenopathy01.09.01.002--Not Available
Lymphocytosis01.02.01.003--Not Available
Macular oedema06.04.06.0050.000080%Not Available
Malaise08.01.01.0030.002312%
Mania19.16.02.0020.000576%
Melaena24.07.02.013; 07.12.02.0040.000160%Not Available
Memory impairment19.20.01.003; 17.03.02.0030.000872%
Menstruation delayed21.01.02.003; 05.05.01.0100.000120%Not Available
Mental disability26.01.01.001--Not Available
Mental impairment19.21.02.003; 17.03.03.0020.000360%Not Available
Microcytic anaemia01.03.02.0080.000160%Not Available
Micturition urgency20.02.02.0060.000080%
Middle insomnia19.02.01.003; 17.15.03.0030.000176%Not Available
Migraine24.03.05.003; 17.14.02.001--Not Available
Miosis17.02.11.002; 06.05.03.0030.001160%Not Available
Monoparesis17.01.04.0110.000080%Not Available
Mood altered19.04.02.0070.000296%Not Available
Mood swings19.04.03.001--Not Available
Mouth haemorrhage24.07.02.014; 07.05.02.0010.000200%
Mouth ulceration07.05.06.004--Not Available
Movement disorder17.01.02.0100.000120%Not Available
Multiple sclerosis17.16.01.001; 10.04.10.0080.000160%Not Available
Muscle rigidity17.05.02.005; 15.05.04.0010.000496%Not Available
Muscle spasms15.05.03.004--
Muscle twitching15.05.03.0050.000360%Not Available
Muscular weakness17.05.03.005; 15.05.06.001--
Mutism19.19.01.001; 17.02.08.0070.000080%Not Available
Myalgia15.05.02.0010.001176%
Mydriasis17.02.11.003; 06.05.03.0040.000360%Not Available
Myocardial infarction24.04.04.009; 02.02.02.007--
The 11th Page    First    Pre   11 12 13 14 15    Next   Last    Total 23 Pages